Bulk Marigold Lutein Supplier (Tagetes erecta) — Lutein 4% Feed Grade, 10%, 50%, 80% | vs Calendula | B2B Wholesale
Valeherb supplies Tagetes erecta (African/Aztec marigold) lutein extract across the purity spectrum — 4% (feed grade), 10%, 50%, and 80% lutein, with custom specifications available. Two botanicals share the common name “marigold” but serve completely different roles: Tagetes erecta is the world’s dominant commercial source of lutein and zeaxanthin for eye-health and food-colorant applications (this is Valeherb’s product line), while Calendula officinalis (pot marigold) is a different plant with a triterpenoid/flavonoid profile used in cosmeceutical and topical products. This guide leads with the Tagetes lutein line and includes a species comparison so buyers specify correctly.
Two Species, Two Applications: The Distinction Every Buyer Must Know
| Species | Common Name | Primary Actives | Main Application |
|---|---|---|---|
| Tagetes erecta (Valeherb product) | African/Aztec marigold | Xanthophyll carotenoids: lutein (dominant), zeaxanthin, cryptoxanthin | Eye-health supplements (macular pigment, blue-light/screen-exposure research areas); food colorant E161b; feed-grade pigmentation |
| Calendula officinalis (comparison) | Pot marigold, garden marigold | Triterpenoids (oleanolic, ursolic acid), flavonoids (isorhamnetin, quercetin), polysaccharides | Cosmeceuticals, topical skin and wound-care products, inflammatory-pathway skincare |
Tagetes erecta: Active Compounds and Available Grades
Lutein and zeaxanthin accumulate in the macula lutea, where they function as a natural optical filter for blue light and quench reactive oxygen species from phototransduction.[1] Tagetes erecta petals are the dominant commercial source of both. In the petal, lutein is present primarily as lutein esters (90–99%); commercial processing saponifies these to the free-form grade used in most clinical trials.
| Grade | Lutein Content | Zeaxanthin | Typical Application |
|---|---|---|---|
| Feed Grade | 4% lutein | Proportional | Animal nutrition — poultry and egg-yolk pigmentation (feed use; not a human supplement specification) |
| 10% Extract | 10% lutein by HPLC | Co-specified | Eye-health capsules, softgels, multivitamin blends |
| 50% Extract | 50% lutein by HPLC | Specified ratio available | Higher-purity eye-health softgels |
| 80% Extract | 80% lutein by HPLC | Specified ratio available | High-purity macular-carotenoid formulations |
Free-form (saponified) and ester forms are available across the supplement grades — specify the form in your inquiry.
Macular Carotenoid Research (Tagetes erecta)
AREDS2 and the Dose Benchmark
The AREDS2 (Age-Related Eye Disease Study 2) is the most cited clinical trial on macular carotenoid supplementation. It studied lutein plus zeaxanthin at 10 mg + 2 mg/day over five years in more than 4,000 participants in an age-related eye-disease population, and the 10 mg + 2 mg combination is widely referenced as the dose benchmark for macular-carotenoid formulations.[1]
Macular Pigment Optical Density (MPOD)
A 6-month randomized, double-blind, placebo-controlled trial by Green-Gomez et al. (2020) in 81 healthy volunteers reported that lutein, zeaxanthin, and meso-zeaxanthin supplementation increased serum carotenoid concentrations and macular pigment optical density (MPOD) versus placebo — directly measuring the retinal-accumulation mechanism studied in relation to blue-light and screen-exposure research.[3] This research area extends the formulation target demographic beyond older age groups.
Calendula officinalis (Comparison — Not a Valeherb Lutein Product)
Calendula officinalis is included here only to help buyers distinguish it from Tagetes lutein; it is a different plant with a different mechanism, used in topical and cosmeceutical products rather than eye-health supplements.
- Skin & wound-care research: A randomized clinical study by Giostri et al. (2022) examined standardized Calendula officinalis extract in acute hand wounds and reported a shorter mean epithelization time versus control.[4]
- Inflammatory-pathway research: Flavonoids (isorhamnetin, quercetin derivatives) are studied for COX-2 and NF-κB pathway activity, of interest for sensitive-skin and redness formulations.
- Skin-barrier & antioxidant: Polysaccharide and pigment fractions are studied in relation to barrier support and UV-induced oxidative stress in topical systems.
Formulation Applications (Tagetes erecta Lutein)
| Application | Recommended Grade | Key Notes |
|---|---|---|
| Eye-health supplements (macular, blue-light) | 10% / 50% / 80% lutein | 10 mg lutein + 2 mg zeaxanthin per serving matches the AREDS2 dose reference[1] |
| Antioxidant multivitamin blends | 10% carotenoid extract | Commonly paired with bilberry anthocyanins in ocular-wellness blends |
| Functional food (natural colorant) | 10% or standard powder | EU approved as natural food colorant E161b; heat-stable in most processing conditions |
| Animal nutrition (pigmentation) | Feed grade 4% | Poultry skin and egg-yolk pigmentation; feed use only, separate from human supplement applications |
Sourcing Criteria
| Criterion | What to Require |
|---|---|
| Species Documentation | Latin name confirmed on COA: Tagetes erecta for eye-health/food/feed applications. “Marigold extract” without species is not an acceptable specification |
| Grade & Intended Use | Specify the grade (4% feed, 10%, 50%, 80%) and intended use. Feed-grade material is for animal nutrition and should not be used in human supplements |
| Lutein Form | Specify free-form (saponified) or ester form. Both are bioavailable at standard doses; free-form matches clinical-trial grades; ester is lower cost for food/feed |
| Lutein:Zeaxanthin Ratio | Specify the ratio on the COA — AREDS2 used roughly 5:1 lutein:zeaxanthin. Confirm both are botanically derived; some suppliers blend in synthetic zeaxanthin |
| Third-Party COA | Lutein (HPLC), zeaxanthin (HPLC), heavy metals (USP <232>), pesticide residues, microbial limits (USP <2021>), moisture — per batch |
| Stability Data | Carotenoids are oxidation-prone — request accelerated stability data (40°C/75% RH). Microencapsulated grades offer better shelf stability in powder formats |
Regulatory Guidance
- US (DSHEA): Lutein and zeaxanthin are established dietary supplement ingredients. Any structure/function claim on the finished product is the marketer’s responsibility to substantiate and must carry the FDA disclaimer; eye-health and antioxidant structure/function claims are the more readily supported areas, drawing on AREDS2 and other published data. Disease claims (e.g., treating or preventing age-related macular degeneration) require drug (NDA) approval
- EU (Food colorant): Lutein from Tagetes erecta is approved as natural food colorant E161b under EU Regulation 1333/2008 — one of the few botanical carotenoids with direct EU food-additive authorization
- Feed use: Feed-grade Tagetes xanthophylls are regulated under animal-feed-additive frameworks, separate from human food and supplement rules — confirm the applicable feed-additive authorization for your market
- EU (Herbal medicinal, Calendula): Calendula officinalis flower has a well-established-use monograph under the EMA (EMA/HMPC/179282/2010) for minor skin inflammation and wound healing — regulatory background for the comparison species[5]
References
[1] Age-Related Eye Disease Study 2 Research Group. (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA, 309(19), 2005–2015. doi:10.1001/jama.2013.4997
[2] Olmedilla-Alonso B et al. (2024). Bioavailability of lutein from marigold flowers (free vs. ester forms): a randomised cross-over study to assess serum response and visual contrast threshold in adults. Nutrients, 16(10), 1415. doi:10.3390/nu16101415
[3] Green-Gomez M et al. (2020). The impact of formulation on lutein, zeaxanthin, and meso-zeaxanthin bioavailability: a randomised double-blind placebo-controlled study. Antioxidants, 9(8), 767. doi:10.3390/antiox9080767
[4] Giostri GS et al. (2022). Treatment of acute wounds in hand with Calendula officinalis L.: a randomized trial. Tissue Barriers, 10(3), 1994822. doi:10.1080/21688370.2021.1994822
[5] European Medicines Agency. (2012). Assessment report on Calendula officinalis L., flos. EMA/HMPC/179282/2010. ema.europa.eu





